A large number of functions have been demonstrated for tenascin-C by antibody perturbation assays and in vitro cell culture experiments. However, these results contrast sharply with the lack of any apparent phenotype in mice with a genetic deletion of tenascin-C. A possible explanation for the lack of phenotype would be expression of some altered but functional tenascin-C in the mutant. We report the generation of an independent tenascin-C null mouse and conclude that the original tenascin-C knockout, which is genetically very similar to ours, is also a true null. As found previously, the absence of tenascin-C has no influence on development, adulthood, life span, and fecundity. We have studied in detail two models of wound healing. After axotomy, the regeneration of the sciatic nerve is not altered without tenascin-C. During healing of cutaneous wounds, deposition of collagen I, fibulin-2, and nidogen is identical in mutant and wild-type mice. In contrast, fibronectin appears diminished in wounds of tenascin-C-deficient mice. However, the lack of tenascin-C together with the reduced amount of fibronectin has no influence on the quality of the healing process.
Tenascin-C is a large hexameric glycoprotein present in extracellular matrices. It is a member of a family of related proteins comprising tenascin-C, tenascin-R, and tenascin-X. All of these proteins are modular proteins containing heptad repeat sequences, epidermal growth factor-like modules, fibronectin type III modules, and a fibrinogen-like domain. The heptad repeat sequences facilitate the formation of hexamers, which are the deposited form of tenascin-C. Different forms of tenascin-C are generated by alternative splicing of various fibronectin type III repeats (for review, see refs. 1 
and 2).
Antibody perturbation assays and in vitro experiments have suggested multiple functions for tenascin-C, including proliferation, cell migration, axon guidance, organogenesis, and tissue repair (1, 2) . The expression pattern of tenascin-C is temporally and spatially restricted during embryonic development and correlates with several important morphogenetic events. It is, for example, distributed along migratory pathways of neural crest cells (3, 4) and at sites of mesenchymalepithelial interactions during organogenesis (5) (6) (7) . Tenascin-C is present in limited levels in adult animals, but the expression rises again during tumor growth and tissue repair. It is highly expressed in the granulation tissue of cutaneous wounds (8) , distal to the lesion during peripheral nerve regeneration after axotomy (9) , and in wounds of the cerebral cortex (10) .
In two reports, it was shown that tenascin-C-deficient mice develop without phenotype (11) and normally repair lesions in the cerebral cortex (12) . These unexpected findings have been questioned by Mitrovic and Schachner (13) , who report the presence of small amounts of a truncated form of tenascin-C in these mutant mice. The functional relevance of this aberrant polypeptide is unclear.
To investigate the function of tenascin-C, we have independently established a tenascin-C-deficient mouse strain that lacks any protein. Tenascin-C-null mice are normal and show no deficits in peripheral nerve regeneration and cutaneous wound healing.
MATERIALS AND METHODS
Generation of Tenascin-C-Deficient Embryonic Stem (ES) Cells and Mice. Genomic clones containing exon 2 of the tenascin-C gene were isolated from a genomic cosmid library derived from mouse strain 129/Sv. The neomycin gene under control of the phosphoglycerokinase promoter was inserted into exon 2, thereby deleting two NcoI fragments containing the signal peptide and the heptad repeat sequences. For negative selection, the thymidine kinase gene from herpes simplex virus (HSV-tk) was cloned to one end of the construct. After electroporation of D3 ES cells (for details, see ref. 14) , neomycin-resistant clones were isolated and analyzed by Southern blot analysis using an external probe (see Fig. 1A ).
Chimeric mice from two independently targeted ES-cell clones were established as described (14) and mated with 129/Sv females to obtain inbred lines carrying the mutated tenascin-C alleles.
Analysis of RNA Transcripts. Total RNA was isolated from cerebellum of newborn animals using RNeasy columns (Qiagen, Chatsworth, CA). For Northern blot analysis, 15 ,ug of total RNA was separated on an agarose gel and transferred to a nylon filter (Zeta-Probe GT, Bio-Rad). Membranes were hybridized with random prime-labeled (Amersham) probes corresponding to a 1340-bp ApaI/HindIII fragment spanning the 3' coding region of tenascin-C (15) and a f3-actin cDNA.
For reverse transcriptase (RT)-PCR analysis, 2 ,gg of total RNA was reversely transcribed into cDNA using random oligonucleotides (GIBCO/BRL) for RNA priming. Onefourth of the reaction was amplified with a primer (5'-CAGGTACTTCTTCACGGAGC-3') located in exon 1 and with a primer (5'-GCAGTCTTCCCCAGTGAAAC-3') located in exon 3. Amplified fragments were purified from agarose gels with Qiaquick columns (Qiagen) and sequenced with PRISM cycle-sequencing kit (Applied Biosystems).
Protein Analysis. For Western blot analysis cerebellum, lung and thymus of newborn or adult animals were solubilized in Laemmli buffer in the presence of f3-mercaptoethanol either individually or pooled. Extracts were separated by SDS/PAGE (5% polyacrylamide gel) and electroblotted to a nitrocellulose membrane. Filters were blocked and separately incubated with the polyclonal anti-tenascin-C antibodies pk7 (16) , "Christmas bleed" (17) , and AS 142 (18) , and with the anti-tenascin-C monoclonal antibody mTN-12 (7). Filters were subsequently incubated with a peroxidase-conjugated secondary antibody, and tenascin-C was visualized using the Amersham enhanced chemiluminescence system. Expression of Recombinant Truncated Tenascin. A truncated form of tenascin lacking the heptad repeats was obtained by deleting anAvaII/ApaLI fragment corresponding to nucleotides 200-545 of the short form of the mouse tenascin-C cDNA (15) . The construct was cloned into the eukaryotic Rc/CMV expression vector (Invitrogen), which was subsequently lipofected into the human embryonic kidney cell line 293 (American Type Culture Collection).
Axotomy of Sciatic Nerve. The left sciatic nerve of three tenascin-C-deficient and three wild-type littermates (6 weeks of age) was cut 10 mm caudal to the sciatic notch. To allow regeneration, the ends of the proximal and distal stumps were kept opposed by a fine epineural suture. Four weeks later, nerves were cut again 8 mm caudal to the initial lesion and labeled with fluorogold as described (19) . Eight days after labeling, the L3 dorsal root ganglia were isolated and cut into 14-gm sections using a cryostat. Neuronal profiles labeled with fluorogold were counted in every fifth section.
Wounding and Preparation of Wound Tissue. For each of two independent experiments, six tenascin-C-deficient and six control mice (6 weeks of age) were anesthetized with avertin solution. The hair on the back was cut and six full-thickness wounds (6 mm in diameter, 3-4 mm apart) were made on the back of each animal by excising the skin and panniculus carnosus. To allow analysis of cell proliferation in the wounds, the nucleoside analogue bromodeoxyuridine (BrdU) (250 mg/hg body weight) was injected i.p. 2 hr before the animals were killed. The mice were killed 5 or 13 days after wounding, and an area of 7-8 mm, which includes the complete epithelial margins, was harvested. Wounds from the middle of the back were embedded in tissue-tech (Jung, Leica GmbH, Germany) for histological analysis, or wounds from the side of the back were frozen in liquid nitrogen and used for RNA analysis.
Microscopical Analysis. Tissue specimens were embedded in tissue-tech, cut into 6-,um sections, and collected on glass slides (Shandon, Pittsburgh). Immunofluorescence analysis was carried out on unfixed sections using a rat monoclonal antibody against mouse tenascin-C (mTN-12; ref. , and neurofilament (1:500) were diluted in phosphate-buffered saline containing 1% BSA. Fluorescence labeling was performed with fluorescein isothiocyanate-conjugated goat anti-rabbit and goat anti-chicken immunoglobulins, and Cy3-conjugated goat anti-rat and donkey anti-goat immunoglobulins, at the dilution indicated by the manufacturer (Jackson ImmunoResearch). All specimens were mounted in elvanol solution and analyzed using an Axiophot fluorescence microscope (Zeiss).
For cell proliferation assays, incorporation of i.p. injected BrdU into DNA of replicating cells was analyzed using mouse anti-BrdU monoclonal antibodies conjugated with fluorescein isothiocyanate following the protocol supplied by the manufacturer (Boehringer Mannheim). Apoptosis was analyzed using the ApopTag detection kit (Oncor).
RESULTS

Establishment of a Tenascin-C-Deficient Mouse Strain.
The targeting strategy to inactivate the tenascin-C gene is outlined in Fig. 1A . The construct was electroporated into ES cells, and targeted clones were identified by Southern blot analysis using the external probe shown in Fig. 1A . Out of 377 doubly resistant clones, 15 were found to contain the targeted allele. The enrichment by negative selection with 1-(2'-deoxy-2'-fluoro-13-D-arabinofuranosyl)-5-iodouracil was 2.7-fold.
Two targeted ES-cell clones were used to establish tenascin-C-deficient mouse strains. Southern blot genotyping (Fig. 1B) showed that among 371 Fl pups, 24.3% were wild type, 52.8% were heterozygous, and 22.9% were homozygous for the tenascin-C mutation. The tenascin-C-deficient mice were analyzed macroscopically as well, as histologically. In agreement with a previous report (11), our tenascin-C-deficient mice derived from two independently targeted ES-cell clones develop normally, display no abnormalities in adulthood, and have a normal life span.
Tenascin-C-Deficient Mice Express Aberrant Tenascin-C mRNA but No Protein. To test whether the mutation leads to a loss of function, the expression of mRNA and protein was examined. Northern blot analysis of RNA derived from cerebellum (Fig. 1C) showed a reduced level of tenascin-C mRNA in heterozygous mice. Low levels of a shorter transcript were detected in homozygous mutant mice. The nature of this shorter mRNA was investigated by RT-PCR using primers located in exons 1 and 3. Using this primer pair, two fragments were amplified ( -/-) exon 1 is directly linked to exon 3, thereby skipping exon 2 with the neomycin cassette. Inspection of the sequences of both aberrant transcripts clearly revealed that the first encountered ATG leads to a frame shift and translation stop after 99 nucleotides in the large fragment and after 18 nucleotides in the small fragment, respectively.
Western blot analysis was performed using different polyclonal and monoclonal anti-tenascin-C antibodies. None of the antibodies used (see Materials and Methods) were able to detect tenascin-C immunoreactivity in pooled extracts of cerebellum, lung, and thymus derived from tenascin-C null newborn mice (Fig. 1E) . Furthermore, the lack of tenascin-C was confirmed also in individual tissues (skin, cerebellum, lung, and thymus; not shown).
To exclude the unlikely possibility that all tested antibodies only recognize epitopes located in the signal peptide and in the heptad repeats, a truncated tenascin-C polypeptide, which, as in the targeting construct, lacks the heptad repeats, was expressed in human cell line 293. The polyclonal antibody pk7 recognized this truncated protein as well as tenascin-C in wild-type mice. However, no immunoreactivity was seen in tenascin-C-deficient mice (Fig. 1F ).
Peripheral Nerve Regeneration Is Normal in Mice Deficient
for Tenascin-C. Since tenascin-C is drastically up-regulated after peripheral nerve lesion (10, 22) , we investigated whether tenascin-C is required for nerve regeneration. To identify regenerated axons, fluorogold was applied 4 weeks after an initial transection of the sciatic nerve, and neuronal profiles were counted in the L3 lumbar dorsal root ganglia 8 days later. The average number of labeled profiles was 371 (±65 SD) in tenascin-C-deficient mice and 390 (±33 SD) in wild-type littermates, indicating that regeneration of the sciatic nerve is equally efficient in mice lacking tenascin-C (Fig. 2) . Furthermore, the number of motor end plates visualized by fluorescein isothiocyanate-labeled anti-neurofilament antibodies on transversal sections of the Musculus soleus was similar in normal and mutant mice (not shown). (E) Protein analysis of pooled extracts from cerebellum, lung, and thymus. In the left and right panels, the same amount of protein was separated on SDS/5% polyacrylamide gels under reduced conditions. (Left) Coomassie staining indicates that all lanes were equally loaded. (Right) Western blot analysis of tenascin-C expression using the pk7 polyclonal antibody followed by enhanced chemiluminescence detection. (F) Expression of a recombinant tenascin-C lacking the heptad repeats. Extracts from cerebellum of normal and tenascin-C-deficient mice were reduced and separated on an SDS/5% polyacrylamide gel together with unreduced supernatant containing the truncated tenascin-C. Tenascin-C was visualized as described in E.
Cutaneous Wound Healing Is Not Significantly Altered in Tenascin-C-Deficient Mice. Since tenascin-C expression is highly increased during cutaneous wound healing (8), tenascin-C-deficient mice and wild-type littermates were wounded. Hematoxylin/eosin staining of tissue from dissected fullthickness wounds suggested that migration and proliferation of keratinocytes was not altered in the mutant mice. Furthermore, the size, cell density, and subsequent contraction of the formed granulation tissue were indistinguishable from normal (Fig. 3) .*** In addition, proliferation (Fig. 3) and apoptosis (not shown) of epidermal keratinocytes and of fibroblasts and macrophages in the granulation tissue were not changed.
Immunostaining showed high levels of tenascin-C in the granulation tissue of control mice and confirmed the absence of tenascin-C in our mutant mouse strain (Fig. 4) . As described in an earlier study, the eschar frequently showed unspecific staining (20) , which is due to the secondary antibodies used. To test whether the expression of other matrix proteins was altered in the absence of tenascin-C, wound tissues were stained for fibulin-2, fibronectin, nidogen, and collagen I. Fibulin-2, which like tenascin-C is highly up-regulated in the granulation tissue during wound healing (20) , was not changed (Fig. 4) , whereas in the granulation tissue of mutant mice, nidogen and collagen I were normally deposited (not shown), and the amount of fibronectin appeared reduced (Fig. 4) . This latter observation was confirmed in three normal and three mutant mice using two different antisera.
DISCUSSION
The spatial and temporal expression pattern of tenascin-C during development as well as the results obtained by antibody perturbation assays and in vitro experiments suggested an important role for tenascin-C in a variety of biological processes such as organogenesis, neurite outgrowth, neural crest migration, and tissue repair. The lack of phenotype in tenascin-C-deficient mice was, therefore, a surprise and a disappointment for many research laboratories and resulted in a discussion as to whether this protein is superfluous or still has an important yet unidentified function. This debate culminated in a recent article by Mitrovic and Schachner (13) that shows the presence of a truncated form of tenascin-C in the tenascin-Cnull mouse from Saga and coworkers (11) , suggesting that at least part of the tenascin-C molecule is still expressed and still functionally active. Such a leaky mutation in the tenascin-C gene was suggested to explain the lack of phenotype (13) .
As Saga and coworkers (11) described the tenascin-C-null mouse, we independently introduced a null mutation into the mouse tenascin-C gene. Whereas Saga and coworkers (11) replaced part of exon 2 (containing the start codon, signal peptide, and heptad repeats) and the 5' region of intron 2 with a f3-galactosidase gene and a neomycin cassette, we exchanged the coding region of exon 2 (containing the signal peptide and heptad repeats) by a neomycin gene, leaving both intron/exon Proc. Natl. Acad. Sci. USA 93 (1996) 5d wound Altogether, the data convincingly show that tenascin-C is not produced in our homozygous mutant mice. The similarity of our mutation and the one reported by Saga and coworkers (11) suggests that the latter also harbors a true null mutation in the tenascin-C gene that might give rise to similar nonfunctional splice products.
Anatomical and histological analyses revealed no abnormalities in our tenascin-C-null mice during both development and postnatal life. This finding is in sharp contrast to the functions that have been assigned to tenascin-C. On the other hand, null mutations in numerous genes thought to be important for normal life show no phenotype (23) (24) (25) Normal axon outgrowth in tenascin-C-null mice was unexpected since tenascin-C is up-regulated in the nerve stump shortly after lesion (10, 22) and since antibodies to tenascin-C delay reinnervation of motor end plates in frog (27) When we analyzed the healing skin wounds of tenascin-Cnull mice, we did not find histopathological alterations. In normal mice, tenascin-C is highly expressed throughout the whole granulation tissue (8, 20) , and it has been suggested that tenascin-C has an influence on the migration and proliferation of keratinocytes at the wounded area. However, at none of the time points analyzed did we find an altered migration or proliferation rates of keratinocytes. Furthermore, the granulation tissue was of normal size and normal cell density in tenascin-C-deficient mice.
We have earlier shown that in addition to tenascin-C, a number of extracellular matrix proteins are up-regulated during cutaneous wound healing (20) . For this study, we analyzed the expression and deposition of extracellular matrix proteins that serve as a quantitative measurement of the granulation tissue or that bind tenascin-C, such as fibulin-2, nidogen (R. Timpl, personal communication) and fibronectin (29) . In agreement with the histology, collagen I is expressed equally in normal and tenascin-C-null mice. In addition, fibulin-2, which shows an increase in expression similar to tenascin-C during healing of skin wounds, and nidogen are normal in mutant mice. However, deposition of fibronectin is reduced in the granulation tissue of tenascin-C-deficient mice. In wildtype animals, both tenascin-C and fibronectin are up-regulated during wound healing. One explanation for the diminished immunoreactivity could be a change in fibronectin structure associated with masking of epitopes. This is very unlikely, because we could confirm the reduction of fibronectin with two antisera generated in different species. Moreover, both antibodies readily detected fibronectin in various other organs of tenascin-C-deficient mice. A second explanation for the reduced deposition of fibronectin is that the lack of tenascin-C could lead to a diminished number of binding sites for fibronectin and, consequently, to a sequestering of the molecule.
This would, however, need first the deposition of tenascin-C, which then serves as a substratum for fibronectin. Lastly, the lack of tenascin-C could make fibronectin accessible to proteases.
Interestingly, the lack of tenascin-C together with the reduction of fibronectin has no influence on wound healing. This clearly shows that mammals must have a number of extracellular matrix proteins that are compensatory and exchangeable during such important processes as tissue repair.
